J&J unloads St. Joseph's aspirin brand; EU blesses Lucentis for new eye use;

@FiercePharma: Should Sharfstein's temp replacement get the job? Article |  Follow @FiercePharma 

> Johnson & Johnson sold its St. Joseph's aspirin brand to a closely held Baltimore company for an undisclosed sum, the companies said. Report

> Valeant Pharmaceuticals said it expects to report quarterly results that could exceed what analysts on average had expected and issued a 2011 outlook that topped their forecasts. News

> Novartis said the European Commission has approved broader application of its Lucentis drug to treat visually impaired patients, giving sales of the drug a potential boost. Story

> Speciality pharmaceutical firm IS Pharma Plc said it would buy Switzerland-based Helsinn Healthcare's Irish commercial operations for 4.4 million euros ($5.72 million) to expand its business in Europe. Item

> A chemical leak has sickened 62 workers at a pharmaceutical factory in eastern China. Article

> Celgene's CEO has a message for long term investors: You would do well to stick with us through 2015 and beyond. Report

> Teva Pharmaceutical Industries is "very much on track" to meet its 2015 financial targets and toned down its language about searching for acquisitions in Brazil. Story

> The global market for medical apps for mobile phones look set to have doubled last year to reach $84.1 million, according to market research firm Kalorama, which attributes the rise to greater use of smartphones by healthcare professionals. News

Biotech News

@FierceBiotech:  Biogen Idec taps two ex-CEOs to head R&D, corporate development. Story | Follow @FierceBiotech

@JohnCFierce: I really want to see the FDA deliver those CRL letters to the public. Long, long overdue. | Follow @JohnCFierce

> Adventrx announces $22.5M capital raise, mulls acquisition. Article 

> Frazier: Merck to make "tough" spending decisions. Report 

> Ardea's Phase II gout drug shows promise. Story 

> Amgen licenses Xencor's early-stage autoimmune drug. News

And Finally... Republican efforts to scrap President Barack Obama's healthcare reform took a hit on Thursday when budget analysts said repeal would add billions of dollars to the federal budget deficit. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.